The clinical presentation is complex and often involves multiple systemic burdens. Early identification and standardised clinical care are essential for improving prognosis. The diagnosis of this disease requires a combination of clinical presentation, imaging inspection, laboratory testing and pathological activation.
The platform can assist in matching teams of authoritative experts at home and abroad to provide accurate diagnostics and treatment regimens. In recent years, with the development of treatment-oriented, immune-regulatory therapy and precision medicine, many previously difficult-to-treat blood tumor diseases have been significantly improved. Treatment requires close monitoring of efficacy and adverse reactions and timely adjustment according to disease changes.
Multidisciplinary collaboration (MDT) is particularly important for the integrated management of HL-associated imaging cells. 2. Visiting China: arranging face-to-face treatment with authoritative experts, developing individualized treatment plans; 3.
Full-service: providing one-stop services such as medical translation, medical care, accommodation arrangements; 4. Long-term follow-up: establishing a chronic disease management archive, continuous monitoring of disease changes and treatment effects.